190 related articles for article (PubMed ID: 32107713)
1. Is There a Role for Chemotherapy in the Era of Targeted Therapies?
Lee JC; Lamanna N
Curr Hematol Malig Rep; 2020 Apr; 15(2):72-82. PubMed ID: 32107713
[TBL] [Abstract][Full Text] [Related]
2. Frontline Therapy of Chronic Lymphocytic Leukemia: Changing Treatment Paradigm.
Sengar M; Jain H; Rajendra A; Rengaraj K; Thorat J
Curr Hematol Malig Rep; 2020 Jun; 15(3):168-176. PubMed ID: 32542586
[TBL] [Abstract][Full Text] [Related]
3. Targeted Therapies in Chronic Lymphocytic Leukemia: Is 2 (or 3) Better Than 1?
Ujjani C; Cheson BD
Cancer J; 2019; 25(6):449-454. PubMed ID: 31764127
[TBL] [Abstract][Full Text] [Related]
4. Current perspectives on the role of chemotherapy in chronic lymphocytic leukemia.
Wendtner CM; Gregor M
Leuk Lymphoma; 2018 Feb; 59(2):300-310. PubMed ID: 28565930
[TBL] [Abstract][Full Text] [Related]
5. The evolving treatment landscape of chronic lymphocytic leukemia.
Schiattone L; Ghia P; Scarfò L
Curr Opin Oncol; 2019 Nov; 31(6):568-573. PubMed ID: 31593975
[TBL] [Abstract][Full Text] [Related]
6. The Evolution of Targeted Therapies in Chronic Lymphocytic Leukaemia.
Gianfelici V; Levato L; Molica S
Curr Hematol Malig Rep; 2020 Aug; 15(4):343-349. PubMed ID: 32500413
[TBL] [Abstract][Full Text] [Related]
7. Current Treatment of Chronic Lymphocytic Leukemia: The Diminishing Role of Chemoimmunotherapy.
Roeker LE; Thompson M; Mato AR
Drugs; 2022 Feb; 82(2):133-143. PubMed ID: 34932207
[TBL] [Abstract][Full Text] [Related]
8. Relevance of Prognostic Factors in the Era of Targeted Therapies in CLL.
Kittai AS; Lunning M; Danilov AV
Curr Hematol Malig Rep; 2019 Aug; 14(4):302-309. PubMed ID: 31049852
[TBL] [Abstract][Full Text] [Related]
9. [Treatment strategies for chronic lymphocytic leukemia in the era of novel targeted therapies].
Kojima K
Rinsho Ketsueki; 2020; 61(9):1275-1280. PubMed ID: 33162526
[TBL] [Abstract][Full Text] [Related]
10. Chemoimmunotherapy Is Not Dead Yet in Chronic Lymphocytic Leukemia.
Brown JR; Kay NE
J Clin Oncol; 2017 Sep; 35(26):2989-2992. PubMed ID: 28742455
[No Abstract] [Full Text] [Related]
11. Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations.
Soumerai JD; Ni A; Darif M; Londhe A; Xing G; Mun Y; Kay NE; Shanafelt TD; Rabe KG; Byrd JC; Chanan-Khan AA; Furman RR; Hillmen P; Jones J; Seymour JF; Sharman JP; Ferrante L; Mobasher M; Stark T; Reddy V; Dreiling LK; Bhargava P; Howes A; James DF; Zelenetz AD
Lancet Haematol; 2019 Jul; 6(7):e366-e374. PubMed ID: 31109827
[TBL] [Abstract][Full Text] [Related]
12. Paving the way for new agents; is standard chemotherapy part of the treatment paradigm for chronic lymphocytic leukemia in the future?
Frustaci AM; Montillo M; Picardi P; Mazzucchelli M; Cairoli R; Tedeschi A
Expert Rev Hematol; 2016 Jul; 9(7):679-93. PubMed ID: 27253240
[TBL] [Abstract][Full Text] [Related]
13. Targeted therapies for CLL: Practical issues with the changing treatment paradigm.
Jain N; O'Brien S
Blood Rev; 2016 May; 30(3):233-44. PubMed ID: 26776345
[TBL] [Abstract][Full Text] [Related]
14. Chronic lymphocytic leukemia and infection risk in the era of targeted therapies: Linking mechanisms with infections.
Hilal T; Gea-Banacloche JC; Leis JF
Blood Rev; 2018 Sep; 32(5):387-399. PubMed ID: 29571669
[TBL] [Abstract][Full Text] [Related]
15. Update on signal inhibitors in chronic lymphocytic leukemia.
Boddu P; Jain N
Clin Adv Hematol Oncol; 2018 Apr; 16(4):279-288. PubMed ID: 29742083
[TBL] [Abstract][Full Text] [Related]
16. Chemoimmunotherapy Versus Targeted Treatment in Chronic Lymphocytic Leukemia: When, How Long, How Much, and in Which Combination?
Brown JR; Hallek MJ; Pagel JM
Am Soc Clin Oncol Educ Book; 2016; 35():e387-98. PubMed ID: 27249745
[TBL] [Abstract][Full Text] [Related]
17. Predictive and prognostic biomarkers in the era of new targeted therapies for chronic lymphocytic leukemia.
Rossi D; Gerber B; Stüssi G
Leuk Lymphoma; 2017 Jul; 58(7):1548-1560. PubMed ID: 27808579
[TBL] [Abstract][Full Text] [Related]
18. Resistance Mechanisms to Targeted Agents in Chronic Lymphocytic Leukemia.
Kittai AS; Woyach JA
Cancer J; 2019; 25(6):428-435. PubMed ID: 31764124
[TBL] [Abstract][Full Text] [Related]
19. Combination of Targeted Drugs to Control Chronic Lymphocytic Leukemia: Harnessing the Power of New Monoclonal Antibodies in Combination With Ibrutinib.
Cramer P; Langerbeins P; Hallek M
Cancer J; 2016; 22(1):62-6. PubMed ID: 26841018
[TBL] [Abstract][Full Text] [Related]
20. A randomized phase II trial comparing chemoimmunotherapy with or without bevacizumab in previously untreated patients with chronic lymphocytic leukemia.
Kay NE; Strati P; LaPlant BR; Leis JF; Nikcevich D; Call TG; Pettinger AM; Lesnick CE; Hanson CA; Shanafelt TD
Oncotarget; 2016 Nov; 7(48):78269-78280. PubMed ID: 27861157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
